drugset / Trial / NCT05742295

Prevention of Cefoperazone-induced Coagulopathy

NCT05742295

Phase 4 Completed 56 enrolled Helwan University
RandomizedParallel-groupDouble-blindPrevention

Summary

Evaluating the effect of prophylactic doses of vitamin K in preventing the adverse effect of cefoperazone/sulbactam induced coagulopathy in critically ill patients.

Timeline

Start
2023-02-25
Primary completion
2023-10-05
Completion
2023-10-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin K Unknown

Indications